Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
14 slides from Bristol-myers Squibb's conference presentation, Jan 12, 2026
Slide 1: Bristol Myers Squibb: Built for Growth
Bristol Myers Squibb: Built for Growth 44th Annual J.P. Morgan Healthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO January 12th, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation (as well as the oral statements made with respect to the information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clini
Slide 3: Our goal
Our goal OPT 1 is to build a company that is financially strong and delivers industry-leading sustainable growth into the 2030s and beyond
Slide 4: Strong execution supports long-term growth objective
Strong execution supports long-term growth objective 2025 Highlights Increased Advanced Completed Implemented further Strengthened Growth Portfolio key pipeline strategic business productivity programs balance sheet sales by 17%* with programs development to and scaled AI to deliver by generating 4
Slide 5: Pipeline assets each with multi-billion-dollar potential
Pipeline assets each with multi-billion-dollar potential Neuroscience Cardiovascular Immunology Oncology Milvexian3 Admilparant Pumitamig8 Iberdomide & 1st-in-class oral M1/M4 Oral factor XIa inhibitor LPA1 antagonist PD-L1 x VEGF-A bispecific antibody Mezigdomide muscarinic agonist Oral CELMoD prot
Slide 6: Significant data expected in 2026…and beyond
Significant data expected in 2026…and beyond NME registrational data LCM pivotal data Key next wave early-stage data 2026 2026 2026 • Admilparant IPF (ALOFT-IPF) • Cobenfy AD Psychosis (ADEPT-1, 2 & 4) • BCMAxGPRC5D dual-targeting CAR T RRMM • Arlo-cel 4L+ MM (QUINTESSENTIAL) • Sotyktu SLE (POETYK S
Slide 7: Drives wave of 10+ new product launch opportunities by 2030
Drives wave of 10+ new product launch opportunities by 2030 Growth Portfolio LCM NME / NME LCM BCMA x GPRC5D CAR T MM Anti-CCR8 Solid tumors RYZ801 HCC Admilparant CD33-GSPT1 MYK-224 Anti-MTBR-Tau IPF AML HFpEF Alzheimer’s Disease Admilparant CD40xFAP PRMT5 TRPC4/5 PPF Solid tumors NSCLC Mood/Anxiet
Slide 8: R&D focused on rigorous execution to deliver high value opportunities
R&D focused on rigorous execution to deliver high value opportunities Science + Execution Value • Pursuing high impact medicines • Ensuring each study has the • Allocating resources to to advance standards of care highest probability of success opportunities with the highest probability of success •
Slide 9: Multiple paths for capital deployment to create value
Multiple paths for capital deployment to create value enabled by financial strength and discipline • Unlocking full potential of the Growth Portfolio Investing in • Prioritizing highest opportunity assets and programs in R&D the business • Deploying AI enterprise-wide • Solid track record of returni
Slide 10: Building our long-term growth profile
Building our long-term growth profile Strategic Priorities Focused on execution Focusing on Financial discipline and and building momentum transformational shareholder friendly in our Growth Portfolio medicines to treat life capital allocation threatening diseases 10
Slide 11: Bristol Myers Squibb
lh Bristol Myers Squibb’
Slide 12: Appendix
Appendix
Slide 13: Clinical Development Portfolio — Phase I and II
Clinical Development Portfolio — Phase I and II Data as of Jan 12th, 2026 Phase I Phase II Anti-CCR8 Solid Tumors 1L Microsatellite Stable Colorectal Cancer BMS-986460^ Prostate Cancer pumitamig 1L Gastric Cancer BMS-986482+ Solid Tumors 1L Triple-Negative Breast Cancer BMS-986488+ Solid T
Slide 14: Clinical Development Portfolio — Phase III
Clinical Development Portfolio — Phase III Data as of Jan 12th, 2026 Phase III Registration US, EU, JP AR LDD Metastatic Castration-Resistant Prostate Cancer OPDIVO 1L Classical Hodgkin Lymphoma (US) atigotatug + nivolumab 1L Extensive-Stage Small Cell Lung Cancer BREYANZI R/R Marginal Zone Lymp
Bristol Myers Squibb — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix